![\"\"](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/07\/4000-helixbiologo.jpg\")
<\/p>\n<\/p>\n
Helix BioPharma Corp. an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announces that, further to its news release dated June 11, 2020, it intends to file its interim consolidated financial statements for the three and nine month periods ended April 30, 2020, related management’s discussion and analysis (“MD&A”) and related management certifications (the “Interim Disclosure Documents”) by July 30, 2020.<\/p>\n
Helix is relying on exemptions granted in Ontario Instrument 51-505 Temporary Exemption from Certain Corporate Finance Requirements <\/em>(the “Blanket Relief”) to extend the deadline for filing its Interim Disclosure Documents, which provides up to a 45-day extension for the filing of certain periodic disclosure documents. The Company would ordinarily have been required to file the Interim Disclosure Documents by June 15, 2020 under National Instrument 51-102 Continuous Disclosure Obligations.<\/em><\/p>\n The Company confirms that its directors, officers and other insiders will be subject to a trading blackout under its Insider Trading and Inside Information Policy and Procedures that reflects the principles of National Policy 11-207 Failure to File Cease Trading Orders and Revocations in Multiple Jurisdictions<\/em> until after the filing of the Interim Disclosure Documents has been completed and the news release regarding the financial results has been widely disseminated. The Company also confirms that there have been no material developments to its business since the Company last provided a business update on June 26, 2020.<\/p>\n About Helix BioPharma Corp. Investor Relations Tags:<\/b> Helix BioPharma Corp.
<\/strong>Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. Helix is a biopharmaceutical company developing unique therapies in the field of immuno-oncology, for the prevention and treatment of cancer, based on its proprietary technology platform DOS47. Helix is currently listed on the TSX under the symbol “HBP”. For more information: https:\/\/www.helixbiopharma.com.<\/p>\n
<\/strong>Helix BioPharma Corp.
9120 Leslie Street, Suite 205
Richmond Hill, Ontario, L4B 3J9
Tel: 905-841-2300
Email: ir@helixbiopharma.com<\/u><\/a><\/p>\nSee Campaign: <\/strong>helixbiopharma.com<\/a>
Contact Information:<\/b>
Helix BioPharma Corp.
\n9120 Leslie Street, Suite 205
\nRichmond Hill, Ontario, L4B 3J9
\nTel: 905-841-2300
\nEmail:ir@helixbiopharma.com<\/p>\n
<\/a>, Wire<\/a>, Disclosure Newswire<\/a>, United States<\/a>, English<\/a><\/p>\n<\/div>\n
\nContact Information:<\/h3>\n
\n9120 Leslie Street, Suite 205
\nRichmond Hill, Ontario, L4B 3J9
\nTel: 905-841-2300
\nEmail:\u00a0ir@helixbiopharma.com<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"Helix BioPharma Corp. an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announces that, further to its news release dated June 11, 2020, it intends to file its interim consolidated financial statements for the three and nine month periods ended April 30, 2020, related management’s discussion and analysis (“MD&A”) … Continue reading Helix BioPharma Corp. Provides Update On The Timing Of Filing Of Third Quarter Results<\/span><\/a> Continue Reading